Company profile
THERIVA BIOLOGICS, INC.
AMEX:TOVXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RIBAXAMASE | phase2 | — | 3 | active |
| ZABILUGENE ALMADENOREPVEC | phase2 | — | 3 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02045589 | phase1 | completed | 2014-01-01 | 2016-10-01 | Theriva Biologics SL | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer |
| NCT02493036 | phase2 | completed | 2015-10-01 | 2015-12-01 | Theriva Biologics, Inc. | A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C |
| NCT02473640 | phase1_2 | completed | 2015-06-01 | 2016-04-01 | Theriva Biologics, Inc. | A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy |
| NCT07701486 | phase1_2 | recruiting | 2026-08-03 | 2027-08-01 | Theriva Biologics SL | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer |
| NCT02563106 | phase2 | completed | 2015-10-01 | 2016-11-01 | Theriva Biologics, Inc. | A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI |
FDA applications (0)
No records yet.